Deruxtecan - Moligand™,≥99% , CAS No.1599440-13-7

CAS: 1599440-13-7 Cat. No.: D646872 Formula: C52H56FN9O13 Peso molecolare: 1034.05
Disponibile su ordine
QUALITÀ & PUREZZA Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. ≥99%
Synonyms
N-(6-(2,5-DIHYDRO-2,5-DIOXO-1H-PYRROL-1-YL)-1-OXOHEXYL)GLYCYLGLYCYL-L-PHENYLALANYL-N-((2-(((1S,9S)-9-ETHYL-5-FLUORO-2,3,9,10,13,15-HEXAHYDRO-9-HYDROXY-4-METHYL-10,13-DIOXO-1H,12H-BENZO(DE)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-1-YL)AMINO)-2-OXOETHOXY)|DERUXTECAN PYRROLE-2,5-DIONE|MAAA-1162a|N-(6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl)glycylglycyl-L-phenylalanyl-N-((2-(((1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo(de)pyrano(3',4':6,7)indolizino(1,2-b)quinolin-1-yl)amino)-2-oxoethoxy|Mc-ggfg-dxd(1)|N-((S)-10-Benzyl-1-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-1,6,9,12,15-pentaoxo-3-oxa-5,8,11,14-tetraazahexadecan-16-yl)-6-(2,5-dioxo-2,5-dih|Deruxtecan [USAN]|N-((S)-5-(2-amino-2-oxoethyl)-7-benzyl-1-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-1,6,9,12-tetraoxo-3-oxa-5,8,11-triazatridecan-13-yl)-6-(2,5-|Deruxtecan|6-(2,5-dioxopyrrol-1-yl)-N-[2-[[2-[[(2S)-1-[[2-[[2-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]amino]-2-oxoethoxy]methylamino]-2
Storage
Protected from light,Store at -20°C,Argon charged
Shipped In
Ice chest + Ice pads
★
Dimensione
Germania (EU)
USA*
Prezzo
Qtà
1mg
D646872-1mg
Su ordinazione · 8–12 settimane
46,77€
5mg
D646872-5mg
Su ordinazione · 8–12 settimane
84,08€
25mg
D646872-25mg
Su ordinazione · 8–12 settimane
234,20€
100mg
D646872-100mg
Su ordinazione · 8–12 settimane
563,94€
Enter a quantity for the sizes you want to add.

Panoramica

Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813).

Specifiche

Sinonimi
N-(6-(2,5-DIHYDRO-2,5-DIOXO-1H-PYRROL-1-YL)-1-OXOHEXYL)GLYCYLGLYCYL-L-PHENYLALANYL-N-((2-(((1S,9S)-9-ETHYL-5-FLUORO-2,3,9,10,13,15-HEXAHYDRO-9-HYDROXY-4-METHYL-10,13-DIOXO-1H,12H-BENZO(DE)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-1-YL)AMINO)-2-OXOETHOXY) | DERUXTECAN PYRROLE-2,5-DIONE | MAAA-1162a | N-(6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol- Mostra altro
Specifiche e purezza
Moligand™,≥99%
Meccanismi biochimici e fisiologici
Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a\nmaleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
Condizioni di conservazione di stoccaggio
Protected from light,Store at -20°C,Argon charged
Spedito in
Ice chest + Ice pads
Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.
Grado
Moligand™
Purezza
≥99%
Nomi e identificatori
SMILES
CCC1(C2=C(COC1=O)C(=O)N3CC4=C5C(CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)NC(=O)COCNC(=O)CNC(=O)C(CC7=CC=CC=C7)NC(=O)CNC(=O)CNC(=O)CCCCCN8C(=O)C=CC8=O)O
IUPAC Name
6-(2,5-dioxopyrrol-1-yl)-N-[2-[[2-[[(2S)-1-[[2-[[2-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]amino]-2-oxoethoxy]methylamino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]hexanamide
InChIKey
WXNSCLIZKHLNSG-MCZRLCSDSA-N
InChI
1S/C52H56FN9O13/c1-3-52(73)33-19-38-48-31(24-62(38)50(71)32(33)25-75-51(52)72)47-35(14-13-30-28(2)34(53)20-36(60-48)46(30)47)58-43(67)26-74-27-57-41(65)22-56-49(70)37(18-29-10-6-4-7-11-29)59-42(66)23-55-40(64)21-54-39(63)12-8-5-9-17-61-44(68)15-16-45(61)69/h4,6-7,10-11,15-16,19-20,35,37,73H,3,5,8-9,12-14,17-18,21-27H2,1-2H3,(H,54,63)(H,55,64)(H,56,70)(H,57,65)(H,58,67)(H,59,66)/t35-,37-,52-/m0/s1
Isomeri SMILES
CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C5[C@H](CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)NC(=O)COCNC(=O)CNC(=O)[C@H](CC7=CC=CC=C7)NC(=O)CNC(=O)CNC(=O)CCCCCN8C(=O)C=CC8=O)O
CAS alternativo
1599440-13-7
Peso molecolare
1034.05

Dati avanzati

Struttura 3D
Modello di struttura chimica interattiva





Certificati (CoA, COO, BSE/TSE e tabella di analisi)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

4 results found

Lot NumberCertificate TypeDataOggetto
C2625338C2625338Certificate of AnalysisMar 03, 2026 D646872
C2625339C2625339Certificate of AnalysisMar 03, 2026 D646872
C2625350C2625350Certificate of AnalysisMar 03, 2026 D646872
C2625365C2625365Certificate of AnalysisMar 03, 2026 D646872
Proprietà chimiche e fisiche
SolubilitàDMSO : 35 mg/mL (33.85 mM; Need ultrasonic)
Sensibilitàlight & Moisture sensitive
Peso molecolare1034.1
XLogP3-0.400
Hydrogen Bond Donor Count7
Hydrogen Bond Acceptor Count15
Rotatable Bond Count22
Exact Mass1033.4 Da
Monoisotopic Mass1033.4 Da
Topological Polar Surface Area301.000 Ų
Heavy Atom Count75
Formal Charge0
Complexity2360.000
Isotope Atom Count0
Defined Atom Stereocenter Count3
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
The total count of all stereochemical bonds0
Covalently-Bonded Unit Count1
Domande frequenti e articoli
Calcolatori di soluzioni
Recensioni

Recensioni dei clienti

Hai bisogno di aiuto per scegliere la qualità?

La nostra guida alla selezione delle qualità copre purezza, stato dello stabilizzatore e idoneità all'applicazione per tutte le varianti del nostro catalogo.

Visualizza la guida alle qualità Moligand™ →

Desidera che le inviamo un messaggio quando avremo sconti disponibili?

Ricordamelo più tardi

Grazie! Controlli la sua casella di posta per confermare.

Ops! Le notifiche sono disabilitate.